CBD stakeholders say they hope the appointment of a cannabis policy expert at the U.S. Food & Drug Administration (FDA) signals the agency may finally begin to establish a regulatory program.
FDA has hired Norman Birenbaum, a former cannabis official in two states, to the position of senior public health advisor in its Center for Regulatory Programs.
“After four years of inaction, we are hopeful that the appointment of Norman Birenbaum by the FDA signals a positive step forward for the regulation of hemp-derived cannabinoids such as CBD,” said Jonathan Miller, General Counsel at the U.S. Hemp Roundtable (USHR).
To read more, click on Hemp Today